Sarepta Therapeutics has started screening participants for a Phase 3 clinical trial to test its gene therapy candidate SRP-9003 in children with limb-girdle muscular dystrophy type 2E; wastewater testing points to a new COVID-19 infection wave fueled by the JN.1 variant; most patients on anti-obesity medications kept at least some weight off up to a year after they stopped taking them.
Data compiled by the Indian SARS-CoV-2 Genomics Consortium (INSACOG) showed Maharashtra has recorded the highest number of JN.1 cases at 477 followed by Karnataka at 249.
India reported 203 Covid cases with an active caseload of 2,034, according to the Union Health Ministry. Two deaths were recorded in Kerala and Maharashtra. The rise in daily cases started after the emergence of a new variant and cold conditions. The JN.1 variant is not causing an exponential rise in cases or a surge in hospitalization and mortality. India has witnessed three COVID-19 waves, with the Delta wave in April-June 2021 being the peak. The country has administered 220.67 crore vaccine doses and has a national recovery rate of 98.81%.
The new Covid-19 sub-variant JN.1 started a new scare among the masses with growing numbers of cases all around the world. The scare was so much that in some parts of the world, people were reminded of old pandemic days.
The latest figures show that England’s current Covid wave is less likely to get people sick enough to be hospitalised, as compared to previous waves.
It means, people who are infected by Covid-19 recently have less to worry about than at any other time during the pandemic, told Paul Hunter at the University of East Anglia in the UK to the NewScientist.
China is likely to see a rebound in Covid-19 infections in January, and the highly transmissible JN.1 variant will become the dominant strain, health authorities have said. COVID-19 Scare: JN.1 Variant To Soon Become Dominant Strain in China, Say Health Officials.